相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。PROSE: Randomized proteomic stratified phase III study of second line erlotinib versus chemotherapy in patients with inoperable non–small cell lung cancer (NSCLC).
C. Sorlini et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Final overall survival results of NEJ002, a phase III trial comparing gefitinib to carboplatin (CBDCA) plus paclitaxel (TXL) as the first-line treatment for advanced non-small cell lung cancer (NSCLC) with EGFR mutations.
A. Inoue et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Advances in Treatment of Lung Cancer With Targeted Therapy
Philip T. Cagle et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2012)
Properties of resistant cells generated from lung cancer cell lines treated with EGFR inhibitors
Gargi Ghosh et al.
BMC CANCER (2012)
A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer
Takashi Kobayashi et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2012)
Recent clinical developments and rationale for combining targeted agents in non-small cell lung cancer (NSCLC)
C. P. Belani et al.
CANCER TREATMENT REVIEWS (2012)
Methylation of death-associated protein kinase is associated with cetuximab and erlotinib resistance
Takenori Ogawa et al.
CELL CYCLE (2012)
High EGFR Gene Copy Number and Skin Rash as Predictive Markers for EGFR Tyrosine Kinase Inhibitors in Patients with Advanced Squamous Cell Lung Carcinoma
Youngjoo Lee et al.
CLINICAL CANCER RESEARCH (2012)
Efficacy of EGFR Tyrosine Kinase Inhibitors in Patients With EGFR-Mutated Non-Small-Cell Lung Cancer: A Meta-Analysis of 13 Randomized Trials
Fausto Petrelli et al.
CLINICAL LUNG CANCER (2012)
Patient-Tailored Treatments with Anti-EGFR Monoclonal Antibodies in Advanced Colorectal Cancer: KRAS and Beyond
A. Ballestrero et al.
CURRENT CANCER DRUG TARGETS (2012)
ALK translocation and crizotinib in non-small cell lung cancer: An evolving paradigm in oncology drug development
Giorgio Scagliotti et al.
EUROPEAN JOURNAL OF CANCER (2012)
Lung cancer in never smokers - A review
Sebastien Couraud et al.
EUROPEAN JOURNAL OF CANCER (2012)
Emerging personalized oncology: sequencing and systems strategies
William Cho et al.
FUTURE ONCOLOGY (2012)
A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing
Young Seok Ju et al.
GENOME RESEARCH (2012)
A computational index derived from whole-genome copy number analysis is a novel tool for prognosis in early stage lung squamous cell carcinoma
Ornella Belvedere et al.
GENOMICS (2012)
Remarkable Tumor Response to Crizotinib in a 14-Year-Old Girl With ALK-Positive Non-Small-Cell Lung Cancer
Su-Jung Kim et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
TAILOR: Phase III trial comparing erlotinib with docetaxel in the second-line treatment of NSCLC patients with wild-type (wt) EGFR.
Marina Chiara Garassino et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations
James Chih-Hsin Yang et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Cancer Genomics: Technology, Discovery, and Translation
Ben Tran et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
EGFR Molecular Profiling in Advanced NSCLC A Prospective Phase II Study in Molecularly/Clinically Selected Patients Pretreated with Chemotherapy
Michele Milella et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
Phase II Study of the Multitargeted Tyrosine Kinase Inhibitor XL647 in Patients with Non-Small-Cell Lung Cancer
M. Catherine Pietanza et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
The mTOR Pathway in Lung Cancer and Implications for Therapy and Biomarker Analysis
Simon Ekman et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
Molecular pathology of lung cancer: key to personalized medicine
Liang Cheng et al.
MODERN PATHOLOGY (2012)
Abstract C191: Preclinical investigation of the antitumor efficacy in lung cancer of Y15, a novel focal adhesion kinase inhibitor.
G. K. Dy et al.
MOLECULAR CANCER THERAPEUTICS (2012)
The EGFR T790M Mutation in Acquired Resistance to an Irreversible Second-Generation EGFR Inhibitor
Youngwook Kim et al.
MOLECULAR CANCER THERAPEUTICS (2012)
EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications
Hiroyuki Yasuda et al.
LANCET ONCOLOGY (2012)
Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial
James Chih-Hsin Yang et al.
LANCET ONCOLOGY (2012)
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
Rafael Rosell et al.
LANCET ONCOLOGY (2012)
Discovery of small molecule cancer drugs: Successes, challenges and opportunities
Swen Hoelder et al.
MOLECULAR ONCOLOGY (2012)
Impact of specific mutant KRAS on clinical outcome of EGFR-TKI-treated advanced non-small cell lung cancer patients with an EGFR wild type genotype
Giulio Metro et al.
LUNG CANCER (2012)
Targeting EGFR in non-small-cell lung cancer: Lessons, experiences, strategies
Giulia M. Stella et al.
RESPIRATORY MEDICINE (2012)
Global Cancer Statistics
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2011)
Phase II Study of Erlotinib as Third-line Monotherapy in Patients with Advanced Non-small-cell Lung Cancer without Epidermal Growth Factor Receptor Mutations
Shun Matsuura et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2011)
Initial phase II results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): PROFILE 1005
L. Crino et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non-Small-Cell Lung Cancer in Asia (IPASS)
Masahiro Fukuoka et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Induction erlotinib or gemcitabine/carboplatin factorial assignment therapy in stage IIIA-N2 non-small cell lung cancer
W. Zhong et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients With Advanced Non-Small-Cell Lung Cancer Considering First-Line EGFR Tyrosine Kinase Inhibitor Therapy
Vicki Leigh Keedy et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis
Alice T. Shaw et al.
LANCET ONCOLOGY (2011)
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
Caicun Zhou et al.
LANCET ONCOLOGY (2011)
New driver mutations in non-small-cell lung cancer
William Pao et al.
LANCET ONCOLOGY (2011)
A multicenter phase II study to evaluate the efficacy and safety of gefitinib as first-line treatment for Korean patients with advanced pulmonary adenocarcinonna harboring EGFR mutations
Dong-Wan Kim et al.
LUNG CANCER (2011)
Personalized medicine in lung cancer: what we need to know
Tony S. K. Mok
NATURE REVIEWS CLINICAL ONCOLOGY (2011)
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Lecia V. Sequist et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
Mutations in the DDR2 Kinase Gene identify a Novel therapeutic target in squamous cell lung cancer
Peter S. Hammerman et al.
CANCER DISCOVERY (2011)
The BATTLE Trial: Personalizing Therapy for Lung Cancer
Edward S. Kim et al.
CANCER DISCOVERY (2011)
EGFR Mutation Is a Better Predictor of Response to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Carcinoma Than FISH, CISH, and Immunohistochemistry
Lynette M. Sholl et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2010)
Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain
Christian C. Lee et al.
BIOCHEMICAL JOURNAL (2010)
Epidermal Growth Factor Receptor Biomarkers in Non-Small-Cell Lung Cancer: A Riddle, Wrapped in a Mystery, Inside an Enigma
Frances A. Shepherd et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Efficacy and safety of PF299804 versus erlotinib (E): A global, randomized phase II trial in patients (pts) with advanced non-small cell lung cancer (NSCLC) after failure of chemotherapy (CT)
M. J. Boyer et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Lung Adenocarcinoma From East Asian Never-Smokers Is a Disease Largely Defined by Targetable Oncogenic Mutant Kinases
Yihua Sun et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Neratinib, an Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor: Results of a Phase II Trial in Patients With Advanced Non-Small-Cell Lung Cancer
Lecia V. Sequist et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
A Phase II Trial of Erlotinib Monotherapy in Pretreated Patients with Advanced Non-small Cell Lung Cancer Who Do Not Possess Active EGFR Mutations Okayama Lung Cancer Study Group Trial 0705
Hiroshige Yoshioka et al.
JOURNAL OF THORACIC ONCOLOGY (2010)
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
Tetsuya Mitsudomi et al.
LANCET ONCOLOGY (2010)
Head and Neck Squamous Cell Carcinoma: New Translational Therapies
Anthony Prince et al.
MOUNT SINAI JOURNAL OF MEDICINE (2010)
The mutation spectrum revealed by paired genome sequences from a lung cancer patient
William Lee et al.
NATURE (2010)
Targeted therapy in non-small-cell lung cancer-is it becoming a reality?
Filip Janku et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2010)
EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors
Young Lim Choi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Anaplastic Lymphoma Kinase Inhibition in Non-Small-Cell Lung Cancer
Eunice L. Kwak et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Personalized Medicine for Pancreatic Cancer: A Step in the Right Direction
Andrew H. Ko et al.
GASTROENTEROLOGY (2009)
First-Line Gefitinib for Patients With Advanced Non-Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations Without Indication for Chemotherapy
Akira Inoue et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Prospective phase II study of gefitinib in non-small cell lung cancer with epidermal growth factor receptor gene mutations
Kenji Sugio et al.
LUNG CANCER (2009)
Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma.
Tony S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Customized Treatment in Non-Small-Cell Lung Cancer Based on EGFR Mutations and BRCA1 mRNA Expression
Rafael Rosell et al.
PLOS ONE (2009)
EGFR tyrosine kinase inhibitors in lung cancer: An evolving story
Lecia V. Sequist et al.
ANNUAL REVIEW OF MEDICINE (2008)
Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403)
K. Tamura et al.
BRITISH JOURNAL OF CANCER (2008)
Deregulated EGFR Signaling during Lung Cancer Progression: Mutations, Amplicons, and Autocrine Loops
Adi F. Gazdar et al.
CANCER PREVENTION RESEARCH (2008)
Advances in Breast Cancer: Pathways to Personalized Medicine
Olufunmilayo I. Olopade et al.
CLINICAL CANCER RESEARCH (2008)
Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group study BR.21
Chang-Qi Zhu et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations
Lecia V. Sequist et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond
Marc Ladanyi et al.
MODERN PATHOLOGY (2008)
Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents:: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer
Helena Linardou et al.
LANCET ONCOLOGY (2008)
Drug therapy: EGFR antagonists in cancer treatment
Fortunato Ciardiello et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Molecular origins of cancer: Lung cancer
Roy S. Herbst et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer
Tetsuya Mitsudomi et al.
CANCER SCIENCE (2007)
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer
Manabu Soda et al.
NATURE (2007)
iTARGET: A phase II trial to assess the response to gefitinib in epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) tumors
L. V. Sequist et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer
Lecia V. Sequist et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Epidermal growth factor receptor mutations in lung cancer
Sreenath V. Sharma et al.
NATURE REVIEWS CANCER (2007)
Oncogenic shock - Turning an activated kinase against the tumor cell
Sreenath V. Sharma et al.
CELL CYCLE (2006)
Update on epidermal growth factor receptor mutations in non-small cell lung cancer
Gregory J. Riely et al.
CLINICAL CANCER RESEARCH (2006)
The epidermal growth factor receptor pathway: A model for targeted therapy
Maurizio Scaltriti et al.
CLINICAL CANCER RESEARCH (2006)
EGF-ERBB signalling: towards the systems level
Ami Citri et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2006)
Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers
H Shigematsu et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
N Thatcher et al.
LANCET (2005)
Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: A Southwest Oncology Group Study
FR Hirsch et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer
F Cappuzzo et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers
H Shigematsu et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain
W Pao et al.
PLOS MEDICINE (2005)
KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib
W Pao et al.
PLOS MEDICINE (2005)
EGF receptor gene mutations are common in lung cancers from never smokers and are associated with sensitivity of tumors to gefitinib and erlotinib
W Pao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
EGFR mutations in lung cancer:: Correlation with clinical response to gefitinib therapy
JG Paez et al.
SCIENCE (2004)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
TJ Lynch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
分享论文
